NCT05597839 - Study of DF9001 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

November 30, 2027

Conditions

Solid Tumor, Adult

Interventions

DRUG

DF9001

Immunotherapy agent targeting NK cells.

DRUG

pembrolizumab

Anti-PD-1 immunotherapy agent

DRUG

KEYTRUDA®

Anti-PD-1 immunotherapy agent

Trial Locations (17)

10029

NOT_YET_RECRUITING

Icahn School of Medicine at Mount Sinai, New York

15232

NOT_YET_RECRUITING

UMPC Hillman Cancer Center, Pittsburgh

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

22031

NOT_YET_RECRUITING

Virginia Cancer Specialists, Fairfax

29425

NOT_YET_RECRUITING

Medical University of South Carolina, Charleston

32224

RECRUITING

Mayo Clinic Jacksonville, Jacksonville

40202

RECRUITING

University of Louisville Hospital, Louisville

45219

RECRUITING

University of Cincinnati, Cincinnati

53792

RECRUITING

University of Wisconsin, Madison

55905

RECRUITING

Mayo Clinic Minnesota, Rochester

64114

WITHDRAWN

AMR Kansas City, Kansas City

85054

RECRUITING

Mayo Clinic Arizona, Phoenix

85234

RECRUITING

Banner MD Anderson, Gilbert

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

92617

RECRUITING

UC Irvine Medical Center, Irvine

08903

RECRUITING

Rutgers, New Brunswick

02903

RECRUITING

Rhode Island Hospital, Providence